Medivir AB (MVR0) Stock Price & Analysis

MVR0 Stock Chart & Stats

€0.12€0.02(15.24%)

At close: Oct 30 5:30 PM GMT+1

Day’s Range: EUR 0.11 - EUR 0.12
52-Week Range: EUR 0.00 - EUR 0.26
Previous Close: EUR 0.11
Volume: 0
Average Volume (3M): 0
Market Cap: EUR 88.26M
Enterprise Value: EUR 754.42M
Total Cash (Recent Filing): N/A
Total Debt (Recent Filing): EUR 0
Price to Earnings (P/E): ―
Beta: 1.78
Next Earnings: Nov 05, 2026 (Est.)
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Medivir AB News

Medivir Updates Share Structure Following LTIP 2023 Conversion

Medivir AB ( ($SE:MVIR) ) just unveiled an announcement. Medivir AB has adjusted its share capital structure following the conversion of 142,365 class C-shares into ordinary shares during September 2026

1M agoMVR0 0GP7

Medivir Bolsters Finances as Fostrox and MIV-711 Advance in Key Phase II Programs

Medivir AB ( ($SE:MVIR) ) just unveiled an announcement. Medivir reported first-half 2026 results showing modest net turnover and negative EBITDA, but a sharply strengthened cash position of SEK 253.5

2M agoMVR0 0GP7

Medivir Expands Share Capital to Fund MIV-711 Orphan Indication

Medivir AB ( ($SE:MVIR) ) has issued an update. Medivir AB has completed an oversubscribed directed share issue that attracted both new and existing institutional investors, underscoring strong market confidence

3M agoMVR0 0GP7

Medivir Shareholders Approve Directed Issue to Bolster Drug Development

Medivir AB ( ($SE:MVIR) ) has shared an update. Medivir AB, a Huddinge-based pharmaceutical developer listed on Nasdaq Stockholm, is focused on innovative treatments for serious conditions with limited therapeutic

3M agoMVR0 0GP7

Medivir secures long-term U.S. patent protection for fostrox–lenvatinib liver cancer combination

The latest announcement is out from Medivir AB ( ($SE:MVIR) ). Medivir AB has secured a Notice of Allowance from the United States Patent and Trademark Office for its patent

3M agoMVR0 0GP7

Medivir Expands Share Capital Following First Tranche of Directed Issue

Medivir AB ( ($SE:MVIR) ) just unveiled an update. Medivir AB has updated its share and vote count following the completion of the first tranche of a directed share issue

4M agoMVR0 0GP7

Medivir Files Disclosure Document for Directed Share Issue on Nasdaq Stockholm

Medivir AB ( ($SE:MVIR) ) has issued an announcement. Medivir has prepared and published a disclosure document in connection with the admission to trading on Nasdaq Stockholm of 85,365,854 new

4M agoMVR0 0GP7

Medivir Calls Extraordinary General Meeting with Expanded Voting Options

Medivir AB ( ($SE:MVIR) ) has shared an announcement. Medivir AB has called an extraordinary general meeting for July 20, 2026, to be held at its premises in Huddinge, with

4M agoMVR0 0GP7

Medivir Raises SEK 140 Million to Accelerate MIV‑711 Development in Rare Pediatric Disease

The latest announcement is out from Medivir AB ( ($SE:MVIR) ). Medivir has raised approximately SEK 140 million through an oversubscribed directed share issue of 85,365,854 new shares at SEK

4M agoMVR0 0GP7

Medivir Plans SEK 130 Million Directed Share Issue to Advance Rare Pediatric Disease Drug

Medivir AB ( ($SE:MVIR) ) has shared an update. Medivir plans to raise approximately SEK 130 million through a directed share issue to Swedish and international institutional investors, with key

4M agoMVR0 0GP7

MVR0 FAQ

What was Medivir AB’s price range in the past 12 months?

Medivir AB lowest stock price was €0.00 and its highest was €0.26 in the past 12 months.

What is Medivir AB’s market cap?

Medivir AB’s market cap is €88.26M.

When is Medivir AB’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Medivir AB’s earnings last quarter?

Medivir AB released its earnings results on Aug 20, 2026. The company reported -€0.003 earnings per share for the quarter, missing the consensus estimate of €0 by -€0.003.

Is Medivir AB overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Medivir AB pay dividends?

Medivir AB does not currently pay dividends.

What is Medivir AB’s EPS estimate?

Medivir AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Medivir AB have?

Medivir AB has 624,179,440 shares outstanding.

What happened to Medivir AB’s price movement after its last earnings report?

Medivir AB reported an EPS of -€0.003 in its last earnings report, missing expectations of €0. Following the earnings report the stock price went up 2.727%.

Which hedge fund is a major shareholder of Medivir AB?

Currently, no hedge funds are holding shares in DE:MVR0

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Medivir AB

Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of medical treatments in areas of high unmet medical need in Sweden, the Nordic region, the rest of Europe, and internationally. The company offers Xerclear (Zoviduo), a combination of a polymerase inhibitor and hydrocortisone for the treatment of labial herpes; and Olysio (simeprevir), a protease inhibitor for the treatment of hepatitis C. It also develops remetinostat, a histone deacetylase (HDAC) inhibitor that is in a Phase II trial for the treatment of mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL), basal cell carcinoma (BCC), and squamous cell carcinoma (SCC); MIV-711, a potent and selective cathepsin K inhibitor that is in a Phase II trial for the treatment of osteoarthritis, as well as in Phase I trials for the treatment of Osteogenesis Imperfecta (brittle bone disease) and Legg-Calvé-Perthes disease (LCPD); and fostroxacitabine bralpamide (fostrox), a liver-targeted inhibitor of DNA replication, which is in Phase I and II trials for the treatment of hepatocellular carcinoma. In addition, the company is developing birinapant, a SMAC-mimetic for the treatment of solid tumors; VBX-1000 (MIC-701), a selective cathepsin K inhibitor for the treatment of canine periodontitis; USP-7, a preclinical research program for the treatment of cancer; and MET-X (MBLI), a preclinical project for the treatment of infection. Medivir AB (publ) was incorporated in 1987 and is based in Huddinge, Sweden.

Medivir AB (MVR0) Earnings & Revenues

Historic Earnings Reports

Technical Analysis

Overall Consensus

Indicator	Bullish	Neutral	Bearish
Overall Consensus	11	5	5
Technical Analysis	2	5	2
Moving Averages	9	0	3

Technical Analysis >

Similar Stocks

Stocks similar to DE:MVR0
Company	Price & Change	Follow
SE:BINVBioInvent International AB
SE:ONCOOncopeptides AB
SE:ISOFOLIsofol Medical AB
SE:CANTACantargia AB
SE:SPRINTSprint Bioscience AB

Compare DE:MVR0 Stocks >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft

MVR0 Stock Chart & Stats

Medivir AB News

Medivir Updates Share Structure Following LTIP 2023 Conversion

Medivir Bolsters Finances as Fostrox and MIV-711 Advance in Key Phase II Programs

Medivir Expands Share Capital to Fund MIV-711 Orphan Indication

Medivir Shareholders Approve Directed Issue to Bolster Drug Development

Medivir secures long-term U.S. patent protection for fostrox–lenvatinib liver cancer combination

Medivir Expands Share Capital Following First Tranche of Directed Issue

Medivir Files Disclosure Document for Directed Share Issue on Nasdaq Stockholm

Medivir Calls Extraordinary General Meeting with Expanded Voting Options

Medivir Raises SEK 140 Million to Accelerate MIV‑711 Development in Rare Pediatric Disease

Medivir Plans SEK 130 Million Directed Share Issue to Advance Rare Pediatric Disease Drug

MVR0 FAQ

Company Description

Medivir AB

Medivir AB (MVR0) Earnings & Revenues

Technical Analysis

Overall Consensus

Similar Stocks

Popular Stocks

Become an Expert with TipRanks Premium